Chinese Journal of Pharmacovigilance ›› 2025, Vol. 22 ›› Issue (5): 570-574.
DOI: 10.19803/j.1672-8629.20241011

Previous Articles     Next Articles

Efficacy and Safety of Panax Quinquefolium Saponin in Adjuvant Treatment of Angina Pectoris of Coronary Heart Disease: a Meta-Analysis

FAN Liping1, LU Shu1, SUN Huiyuan2,*   

  1. 1Department of Pharmacy, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China;
    2Office of Internet Diagnosis and Treatment, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China
  • Received:2024-12-20 Online:2025-05-15 Published:2025-05-19

PDF (PC)

96

Supplement

1

Abstract: Objective To evaluate the efficacy and safety of Panax quinquefolium saponin (Xinyue capsules) in treating angina pectoris of coronary heart disease. Methods Cochrane, PubMed, Embase, Web of Science, ClinicalTrials, SinoMed, CNKI, Wanfang and VIP Data Knowledge Service Platform were searched for literature on randomized controlled trials (RCTs) related to the efficacy and safety of Panax quinquefolium saponin in treating angina pectoris of coronary heart disease. Literature bias risk was assessed using the Cochrane risk of bias 2.0 tool (RoB 2.0) from the inception to Feb 28, 2025. RevMan 5.3 software was used for Meta-analysis and sensitivity analysis while GRADE was employed for quality evaluation of outcome indicators. Results A total of 11 articles were included in this study. Meta-analysis results showed that the clinical effective rate[RR=1.24, 95%CI(1.16, 1.32), P<0.000 01], improvement of angina symptoms(duration of angina pectoris[MD=-2.45, 95%CI(-3.54, -1.37), P<0.000 01] and frequency of angina pectoris[MD=-1.22, 95%CI(-1.80, -0.65), P<0.000 1], myocardial injury indexes{BNP[MD=-52.36, 95%CI(-87.35,-17.37), P=0.003]、CK-MB[MD=-4.56, 95%CI(-0.74,-0.08), P=0.000 7]、cTnI[MD=-0.41, 95%CI(-87.35,-17.37), P=0.01] and H-FABP[MD=-1.86, 95%CI (-3.35,-0.37), P=0.01]} in the panax quinquefolium saponin (Xinyue capsule) group were better than in the Western medicine group. However, there were no significant differences between the two groups in incidence of adverse reactions, such as dizziness, headache, flushing or those involving the digestive tract, liver function and kidney function. Conclusion Panax quinquefolium saponin (Xinyue capsules) can effectively improve the curative effect, symptoms and myocardial injury indexes in the treatment of angina pectoris of coronary heart disease without increasing adverse reactions. However, due to the limitation of the number, sample size and quality of the included studies, more high-quality studies are needed.

Key words: Panax Quinquefolium Saponin, Xinyue Capsule, Angina Pectoris of Coronary Heart Disease, Randomized Controlled Trials(RCTs), Efficacy, Safety, Meta-Analysis

CLC Number: